



## Role of Immune Checkpoint Inhibitors or Targeted Therapy in the Treatment of Patients with Melanoma Volume II

Guest Editors:

**Dr. Henrik Schmidt**

Department of Oncology, Aarhus University Hospital, DK-8200 Aarhus, Denmark

**Dr. Eva Ellebæk**

Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte, DK-2730 Herlev, Denmark

Deadline for manuscript submissions:

**closed (20 September 2024)**

### Message from the Guest Editors

The past few years have brought revolutionary new treatments to melanoma patients, including checkpoint inhibitors and targeted therapy for both patients receiving adjuvant treatment as well as treatment for metastatic disease. Melanoma has become a model disease for developing new immunotherapies, and new drugs are constantly under development. We are very much in need of more knowledge about biomarkers to select the right patient for the right treatment, to become more effective at treating the immune-mediated adverse events in these patients, and to overcome immune resistance. We need to examine the effect of these new treatment strategies in all subgroups of melanoma patients, including ocular and mucosal melanoma, and we need to explore treatment combinations, as well as real-life benefits.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)